Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
EuroSIDA
HIV/AIDS
Framework programme: 5
Project number:
QLK2-CT-2000-00773
EC contribution: € 1 150 000
Duration: 48 months
Type: CA
Starting date: 1 December 2000
Website: http://www.eurosida.org
Graphic element The EuroSIDA network 2000-200: Clinical and Virological Outcome of European Patients Infected with HIV
Keywords: HIV; AIDS; observational study; cohort; virology; clinical outcome

Summary:

The primary objective of the EuroSIDA study is to collect demographic, clinical, therapeutic and laboratory data on patients with HIV infection to determine the long-term virological and clinical outcome for patients from Europe. This knowledge will also be analysed, discussed and presented within the scientific community to assist physicians and public health officials.

Problem:

Despite recent improvement in the prognosis of HIV-infected patients from across Europe due to the use of powerful combination antiretroviral therapies, challenges persist in relation to the durability of responses and new co-morbidities. These challenges mainly concern development of resistance to existing treatments and coping with adverse drug reactions. In addition, there is a dramatic progression in the HIV epidemic in Eastern European countries requiring development of treatment strategies in this setting.

Aim:

The aim of this project is to continue a long-term, prospective collection of clinical, laboratory and therapeutic data as well as plasma on a large cohort of consecutive-HIV-infected patients from across Europe. This in order to assess the factors associated with the clinical, immunological and virological course of HIV infection, including the effect and toxicity of antiretroviral agents and other therapeutic interventions.

There will be a continuation of providing and developing a surveillance system to describe temporal changes and regional differences in the clinical course of HIV. These include:

1) the overall pattern of HIV-related diseases and death, and the emergence of new diseases, including drug-related diseases
2) the prevalence of patients with severe immunosuppression and high viral replication
3) the virological response to initial antiretroviral therapy.

Expected results:

  • Long-term prospective follow-up on 10 900 unselected patients from 70 clinical centres in 26 European countries, providing 40 500 person-years of follow-up.
  • The EuroSIDA main database will serve as a tool to study the course and evolution of chronic HIV infection in patients from across Europe in the future.
  • The study will collect extensive information on adverse events, including risk factors for, and the occurrence of, cardiovascular disease events.
  • In 1999, Poland, the Czech Republic and Hungary entered EuroSIDA. Additional recruitment from the Newly Associated States in the eastern part of Europe (Slovakia, Estonia, Latvia, Lithuania, Romania and Ukraine) will continue in 2002 and 2004.
  • A central plasma repository of 27 000 samples will allow laboratory analyses related to HIV resistance and HIV sub-typing.

Potential applications:

The results are widely disseminated by publications in peer-reviewed journals and are used by health authorities to formulate treatment guidelines. Findings related to the objectives listed above provide important knowledge for decision-making in clinical practice in the care of HIV patients.

Coordinator:

Jens D. Lundgren
Hvidovre University Hospital
Department of Infectious Diseases
144, Kettegaard Alle 30
2650 Hvidovre
Denmark
Tel: +45 36323015
Fax: +45 36473340
E-mail: jdl@cphiv.dk
Website: http://www.eurosida.org

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Schlomo StaszewskiJ.W.Goethe University Hospital
Zentrum der Inneren Medizin
Infektionsambulanz/ Medizinsche Klinik III/Haus 68
Theodor-Stern-Kai 7
DE-60590 Frankfurt am Main
Germany
Tel: +49 696 3017688
Fax: +49 696 3016051
E-mail: staszewski@em.uni-frankfurt.de
3Christoph ManegoldBernhard Nocht Institute for
Tropical Medicine, Clinical Department
Bernhard Nocht Strasse 74
DE-20359 Hamburg
Germany
Tel: +49 40 42818370
Fax: +49 40 42818394
E-mail: manegold@bni.uni-hamburg.de
4Anne JohnsonRoyal Free and U.C. Med. School
Department of Primary Care and Population Sciences
Royal Free Campus
Rowland Hill Street
UK-NW3 2 PF London
United Kingdom
Tel: 44 20 7472 6754
Fax: +44 20 7794 1224
E-mail: a.johnson@pcps.ucl.ac.uk
5Peter ReissAcademisch Ziekenhuis bij de
Universiteit van Amsterdam
Building T, Room T0-123
Meibergdreef 9
NL-1105 AZ Amsterdam
The Netherlands
Tel: +31 2 0566 4479
Fax: +31 2 0691 8821
E-mail: p.reiss@amc.uva.nl
6Nathan ClumeckCHU Saint-Pierre
Department of Infectious Diseases (PL5)
322, rue Haute
BE-1000 Brussels
Belgium
Tel: +32 2 535 4131
Fax: +32 2 539 3614
E-mail: ID-HIV-RESEARCH@stpierre-bru.be
7Christine KatlamaHopital de la Pitié-Salpêtriére
Dept de Medicine Tropicale
Boulevard de l'Hopital 83
FR-75013 Paris, Cedex 13
France
Tel: +33 1 42 16 01 30
Fax: +33 1 42 16 01 26
E-mail: christine.katlama@psl.ap-hop-paris.fr
8Antonio ChiesiIstituto Superiore di Sanità
Laboratory of Virology
Viale Regina Elena, 299
IT-00161 Rome
Italy
Tel: +39 06 4990 3304
Fax: +39 06 4990 2012
E-mail: terapiaantivirale@interbusiness.it
9Jose M. GatellHospital Clínic de Barcelona
Unidad de Enfermedades Infecciosas
Villaroel, 170
ES-08 036 Barcelona
Spain
Tel: +34 9 3227 5430
Fax: +34 9 3451 4438
E-mail: Gatell@medicina.ub.es
10Andrzej HorbanWojewodzki Szpital Zakazny
Centrum Diagnostyki i Terapii AIDS
Wolska st. 37
PL-01-201Warszaw
Poland
Tel: +48 22 632 0611
Fax: +48 22 335 5335
E-mail: ahorban@cdit-aids.med.pl

 
 
top
Graphic element